Literature DB >> 21823142

Interval estimation in two-stage, drop-the-losers clinical trials with flexible treatment selection.

Dan Neal1, George Casella, Mark C K Yang, Samuel S Wu.   

Abstract

In a two-stage, drop-the-losers clinical trial, researchers choose the 'best' among a number of treatments at an interim analysis after the first stage. The selected treatment continues to the second stage for confirmation of efficacy, and the remaining treatments (the 'losers') are dropped from the study. Wu et al. (Biometrika 2010; 97:405-418) showed how to construct confidence limits for the mean difference between the selected treatment and the control when the treatment is chosen after the first stage based on the highest efficacy in the primary clinical endpoint. In this article, we show how to construct a lower confidence limit for the mean difference when the treatment is chosen based on first-stage safety data, early endpoint efficacy data, a combination of safety and efficacy data or any other prespecified selection rule. The result extends the applicability of drop-the-losers designs, for in practice, the 'best' treatment often is not chosen for efficacy alone.
Copyright © 2011 John Wiley & Sons, Ltd.

Mesh:

Year:  2011        PMID: 21823142     DOI: 10.1002/sim.4308

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Testing for efficacy in adaptive clinical trials with enrichment.

Authors:  Samuel S Wu; Yi-Hsuan Tu; Ying He
Journal:  Stat Med       Date:  2014-02-27       Impact factor: 2.373

2.  Estimation after subpopulation selection in adaptive seamless trials.

Authors:  Peter K Kimani; Susan Todd; Nigel Stallard
Journal:  Stat Med       Date:  2015-04-22       Impact factor: 2.373

3.  Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19.

Authors:  Nigel Stallard; Lisa Hampson; Norbert Benda; Werner Brannath; Thomas Burnett; Tim Friede; Peter K Kimani; Franz Koenig; Johannes Krisam; Pavel Mozgunov; Martin Posch; James Wason; Gernot Wassmer; John Whitehead; S Faye Williamson; Sarah Zohar; Thomas Jaki
Journal:  Stat Biopharm Res       Date:  2020-07-29       Impact factor: 1.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.